Ingevity (NGVT) to Release Quarterly Earnings on Wednesday

Key Points

• Ingevity (NGVT) will report Q1 2026 results after the close on May 6, with analysts projecting EPS $0.84 and revenue of $254.73 million, and the company has set FY2026 guidance at EPS 4.80–5.20.
• In the prior quarter Ingevity missed estimates (reported $0.58 vs. $0.74 expected) with revenue down 3.2% year-over-year, and analysts now expect about $5 EPS for the current fiscal year and $6 for the next.
• Shares trade near $74.77 with a $2.64 billion market cap and a 52-week range of $31.91–$77.62; analyst ratings are mixed (2 Buy, 2 Hold, 1 Sell) with a consensus target of about $80 and institutional ownership around 91.6%.

Ingevity (NYSE:NGVT - Get Free Report) is projected to post its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Ingevity to post earnings of $0.84 per share and revenue of $254.7330 million for the quarter. Ingevity has set its FY 2026 guidance at 4.800-5.20 EPS. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 10:00 AM ET.

Ingevity (NYSE:NGVT - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.74 by ($0.16). The firm had revenue of $255.10 million during the quarter, compared to the consensus estimate of $257.27 million. Ingevity had a positive return on equity of 126.25% and a negative net margin of 13.51%.The company's revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.95 EPS. On average, analysts expect Ingevity to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Ingevity Trading Down 2.0%

Ingevity stock opened at $74.77 on Wednesday. The stock has a market cap of $2.64 billion, a P/E ratio of -16.08 and a beta of 1.27. Ingevity has a fifty-two week low of $31.91 and a fifty-two week high of $77.62. The firm's fifty day moving average price is $70.86 and its 200-day moving average price is $63.42. The company has a debt-to-equity ratio of 39.10, a quick ratio of 0.79 and a current ratio of 1.33.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. BMO Capital Markets reaffirmed an "outperform" rating and issued a $83.00 price target on shares of Ingevity in a report on Monday, March 2nd. Wall Street Zen cut shares of Ingevity from a "buy" rating to a "hold" rating in a report on Saturday, April 4th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $82.00 price target on shares of Ingevity in a report on Thursday, February 26th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Ingevity in a report on Tuesday, April 21st. Finally, Wells Fargo & Company upped their price target on shares of Ingevity from $65.00 to $75.00 and gave the stock an "equal weight" rating in a report on Friday, February 27th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $80.00.

Institutional Trading of Ingevity

Several large investors have recently modified their holdings of NGVT. Global Retirement Partners LLC bought a new stake in shares of Ingevity in the fourth quarter worth about $27,000. Meeder Asset Management Inc. bought a new stake in shares of Ingevity in the fourth quarter worth about $33,000. Geneos Wealth Management Inc. grew its stake in shares of Ingevity by 85.8% in the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company's stock worth $36,000 after purchasing an additional 387 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Ingevity in the second quarter worth about $46,000. Finally, Kestra Advisory Services LLC bought a new stake in shares of Ingevity in the fourth quarter worth about $47,000. 91.59% of the stock is owned by institutional investors.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.